Hepatitis B Outcomes After Switching to Long-Acting Cabotegravir/Rilpivirine in People With HIV: Reactivation, Incident Infection, and Liver Safety Across Diverse Serological Profiles
LA-CAB/RPV appears safe in individuals with prior HBV exposure, including those with isolated anti-HBc. Comprehensive HBV screening, vaccination, and liver monitoring are essential.
Authors
- Júlia Calvo (ORCID: https://orcid.org/0000-0003-4663-2970)
- B. Torres
- J. Ambrosioni
- Alberto Foncillas (ORCID: https://orcid.org/0000-0001-9253-3186)
- E Martinez
- Leire Berrocal
- Julia Blanco
- Monserrat Laguno
- José M Miró
- Abiu Sempere
- Lorena de la Mora
- Iván Chivite
Institutions
- Instituto de Salud Carlos III (ES)
- Centro de Investigación Biomédica en Red (ES)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- Clinical Infectious Diseases
- Published
- 2026-01-12
- DOI
- https://doi.org/10.1093/cid/ciag023
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00